The Journal for ImmunoTherapy of Cancer, an open access, peer-reviewed journal, serves as the global voice of the Society and examines all aspects of tumor immunology and cancer immunotherapy from basic research through clinical application. Learn more.
The Forward Fund is an initiative established by SITC to stimulate the future of the science, development and application of cancer immunology and immunotherapy through financially supporting education and research. Learn more.
FDA approves Opdivo to treat advanced form of kidney cancer – U.S. FDA
November 23, 2015
SITC 2015 Special Edition Immune Monitor – November 2015
November 17, 2015
SITC Expands Global Reach, Elects Key Opinion Leaders to the Board
October 21, 2015